探索TNNI3基因中的c.406 C > T变异:对限制性心肌病的病原性洞察力
Tannaz Masoumi1, Hamed Hesami1, Majid Maleki2
1Rajaie Cardiovascular Institute, Tehran, Iran.
BMC medical genomics
|April 30, 2025
概括
在TNNI3基因 (c.406 C>T) 中发现了一种新型的可能致病变体,被确定为患者限制性心肌病 (RCM) 的原因,这突显了遗传性心脏病遗传性检测的重要性.
科学领域:
- 遗传学和分子生物学
- 心脏病学 心脏病学
- 生物化学 生物化学
背景情况:
- 限制性心肌病 (RCM) 是一种罕见的心脏疾病,由透静功能障碍和心肌硬性定义.
- 遗传变异经常与RCM的病因有关.
- 了解RCM的遗传基础对于诊断和管理至关重要.
研究的目的:
- 通过使用综合遗传分析,对被诊断为RCM的患者的遗传基础进行调查.
- 识别和描述与RCM相关的新型遗传变异.
- 在RCM中建立基因型-表型相关性.
主要方法:
- 整个外体序列测序 (WES) 在试验对象上进行.
- 桑格测序证实了已识别的变种,并评估了家族隔离.
- 在 silico 工具和蛋白质结构建模中评估了变体的功能影响.
主要成果:
- 在TNNI3基因中确定了一种可能的致病变体,c.406 C>T,导致一个截断的TNNI3蛋白.
- 生物信息学分析揭示了显著的结构性蛋白质破坏,可能会损害肉髓功能.
- 患者表现出生长迟缓,呼吸不全和心声回声检查结果与RCM一致,父母是异合体携带者,这表明自身逆性遗传.
结论:
- 在TNNI3中发现的新型c.406C>T变异被认为是RCM的潜在致病驱动因素.
- 遗传评估对于早期诊断和遗传性心肌病的管理至关重要.
- 需要进一步的研究来探索TNNI3相关RCM的治疗策略.
相关概念视频
Translation
140.8K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
140.8K
Single Nucleotide Polymorphisms-SNPs
13.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
13.6K


